GWPH - GW Pharmaceuticals plc

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
137.29
+2.79 (+2.07%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous close134.50
Open136.16
Bid136.50 x 800
Ask137.50 x 1200
Day's range134.25 - 137.41
52-week range90.14 - 179.65
Volume537,519
Avg. volume509,390
Market cap4.441B
Beta (3Y monthly)3.43
PE ratio (TTM)N/A
EPS (TTM)-10.61
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est173.17
Trade prices are not sourced from all markets
  • These Three Cannabis Stocks Are in the Green Today
    Market Realist2 days ago

    These Three Cannabis Stocks Are in the Green Today

    These Three Cannabis Stocks Are in the Green TodayINSYS TherapeuticsToday, INSYS Therapeutics (INSY) is trading at $4.69, up ~8.80% from its close of $4.31 on January 16. On January 16, INSY rose ~2.62% to $4.31 from its previous close of $4.20 on

  • GlobeNewswire2 days ago

    Mugglehead reveals a number of stocks set to take advantage of hemp

    It’s one of the world’s fastest growing plants—a separate species of the cannabis sativa genus that, due to its 0.3% tetrahydrocannabinol (THC) content, makes it literally almost impossible to get high from smoking it. Just weeks ago, U.S. President Trump signed the 2018 Farm Bill into law. The newly revamped bill legalizes industrial hemp in the U.S., and in doing so not only makes hemp and CBD eligible for lucrative federal crop insurance, but also removes CBD from the Controlled Substances Act.

  • These Cannabis Stocks Are Soaring in January
    Market Realist3 days ago

    These Cannabis Stocks Are Soaring in January

    These Cannabis Stocks Are Soaring in JanuaryCannabis stock trendsCannabis stock CannTrust Holdings (CNTTF) rose to $6.0 on January 15 from $4.8 at the close of market on December 31, 2018, representing a rise of ~25% in the first half of January

  • The Must-See Marijuana Commentary From the U.S. Surgeon General
    Motley Fool7 days ago

    The Must-See Marijuana Commentary From the U.S. Surgeon General

    The nation's top doctor shows that calls for cannabis reform aren't falling on deaf ears.

  • How Is INSYS Therapeutics Financially Positioned in January?
    Market Realist7 days ago

    How Is INSYS Therapeutics Financially Positioned in January?

    Cannabis Stock INSYS Therapeutics Is on the Rise in January (Continued from Prior Part) ## Revenue trends In the first nine months of 2018, INSYS Therapeutics’ net revenues declined ~40% YoY to reach $109.2 million from $65.7 million. In the third quarter, the company’s revenues declined ~40% YoY to reach $18.3 million from $30.7 million. Wall Street analysts estimate that INSYS Therapeutics is expected to generate revenues of $17.95 million in the fourth quarter of fiscal 2018, which represents a ~42.99% YoY decline. Analysts also estimate that INSYS Therapeutics will report net revenues of $83.74 million for fiscal 2018, which represents a ~40.48% YoY decline. Analysts estimate that GW Pharmaceuticals (GWPH) and Cara Therapeutics (CARA), INSYS Therapeutics’ peers in the cannabinoid drugs market, will report net revenues of $8.7 million and $10.9 million, respectively. GW Pharmaceuticals is expected to deliver ~13.52% YoY revenue growth in fiscal 2018. INSYS Therapeutics and Lunatus signed a licensing agreement for the commercialization of Subsys in the Middle East market. The agreement could boost INSYS Therapeutics’ global footprint and business growth. ## Expenditure trends In the first nine months of 2018, INSYS Therapeutics’ cost of revenue amounted to $8.2 million compared to $16.0 million in the same period the prior year. Wall Street analysts anticipate INSYS Therapeutics’ cost of revenue to be around $9.7 million in fiscal 2018. In the first nine months of 2018, INSYS Therapeutics’ net expenses in sales and marketing (or S&M) amounted to $25.5 million compared to $41.7 million in the same period the prior year. INSYS Therapeutics reported R&D (research & development) and G&A (general & administrative) expenses of $43.2 million and $29.3 million, respectively, compared to $46.6 million and $31.8 million in the same period the prior year. Wall Street analysts estimate that the company’s S&M, G&A, and R&D expenditure will be around $32.49 million, $89.50 million, and $58.78 million, respectively, in fiscal 2018. Continue to Next Part Browse this series on Market Realist: * Part 1 - Cannabis Stock INSYS Therapeutics Has Risen 28% in January * Part 3 - How INSYS Therapeutics’ Earnings Were Trending

  • Cannabis Stock INSYS Therapeutics Has Risen 28% in January
    Market Realist8 days ago

    Cannabis Stock INSYS Therapeutics Has Risen 28% in January

    On January 10, INSYS Therapeutics stock closed at $4.49, which represents ~28% growth from its stock price of $3.50 at the close of market on December 31. On January 2, 2019, INSYS Therapeutics stock price grew ~24.29% to reach $4.35 from its prior day close of $3.50 on December 31, 2018.

  • Here Are Some of GW Pharmaceuticals’ Key Growth Drivers
    Market Realist8 days ago

    Here Are Some of GW Pharmaceuticals’ Key Growth Drivers

    Cannabis Stock GW Pharmaceuticals Growing Steadily in January (Continued from Prior Part) ## Growth drivers The US FDA (Food and Drug Administration) confirmed GW Pharmaceuticals’ (GWPH) Epidiolex seven-year orphan drug exclusivity. The company anticipates a six-month extension for orphan drug exclusivity for pediatric patients. The USPTO granted major favorable patents associated with the use of CBD in epilepsy. The patents include claims for certain seizure types related to Dravet syndrome and LGS. The patents of GW Pharmaceuticals’ Cannabinoids will expire only after 2035. The market exclusivity, orphan drug exclusivity, and patents are expected to boost Epidiolex’s growth in 2019 and beyond. ## Growth opportunities GW Pharmaceuticals completed three phase 3 trials in Europe with Sativex (nabiximos), which all produced positive results. GW Pharmaceuticals targets Sativex approval for the treatment of multiple sclerosis spasticity. The company received regulatory approval in 25 countries outside the US for the treatment of individuals with spasticity associated with multiple sclerosis. GW Pharmaceuticals is conducting research for evaluating the potential of Sativex for the treatment of schizophrenia and other neurological disorders. GW Pharmaceuticals conducted phase 2 trials of CBD:THC for the evaluation of its efficacy in the treatment of Glioblastoma. GW Pharmaceuticals received an orphan drug designation from the US FDA and EMA (European Medicines Agency) for CBD:THC for the treatment of Glioblastoma. GW Pharmaceuticals has also completed a phase 1 trial of its Neonatal Hypoxic-Ischemic Encephalopathy intravenous CBD program. The company anticipates initiating a phase 2 trial during the first half of 2019. THC could boost the company’s growth in the long term. The growth of GW Pharmaceuticals could boost the share prices of the Horizons Marijuana Life Sciences Index ETF (HMLSF). GW Pharmaceuticals makes up ~9.27% of HMLSF’s total portfolio holding. Browse this series on Market Realist: * Part 1 - GW Pharmaceuticals Has Already Soared 23% in January * Part 2 - A Look into GW Pharmaceuticals’ Revenue Trends * Part 3 - How GW Pharmaceuticals’ Earnings Are Trending

  • How GW Pharmaceuticals’ Earnings Are Trending
    Market Realist8 days ago

    How GW Pharmaceuticals’ Earnings Are Trending

    Cannabis Stock GW Pharmaceuticals Growing Steadily in January (Continued from Prior Part) ## Earnings trends In fiscal 2018, GW Pharmaceuticals (GWPH) reported net income and EPS of -$295.2 million and -$0.88, respectively, compared to -$170.5 million and -$0.56 in the prior year. In the fourth quarter of 2018, GW Pharmaceuticals reported net income and EPS of -$79.9 million and -$0.23, respectively, compared to -$53.9 million and -$0.18 in the same period the prior year. ## Expenditure trends In fiscal 2018, GW Pharmaceuticals (GWPH) reported cost of product sales of $6.0 million compared to $4.5 million in fiscal 2017. In fiscal 2018, the company’s R&D (research and development) and SG&A (selling, general, and administrative) expenses amounted to $153.7 million and $141.8 million, respectively, compared to $112.2 million and $58.0 million in fiscal 2017. ## Growth drivers GW Pharmaceuticals’ Epidiolex demonstrated a positive result and achieved the primary endpoint in a phase 3 clinical trial that evaluated the efficacy parameters of the drug for the treatment of Dravet syndrome. In the clinical trial, both the doses of Epidiolex (10 mg/kg/day and 20 mg/kg/day) demonstrated statistically significant improvements in the secondary endpoint parameters compared to a placebo therapy. GW Pharmaceuticals also completed patient recruitment for its phase 3 trial of Epidiolex for the evaluation of its safety and efficacy parameters for the treatment of individuals with Tuberous Sclerosis Complex. The company anticipates data from the clinical trial in the first half of 2019 and expects submission of a supplemental new drug application (or sNDA) to the FDA (Food and Drug Administration) in the second half of 2019. The label expansion of Epidiolex could significantly boost the sales growth of the drug. Continue to Next Part Browse this series on Market Realist: * Part 1 - GW Pharmaceuticals Has Already Soared 23% in January * Part 2 - A Look into GW Pharmaceuticals’ Revenue Trends * Part 4 - Here Are Some of GW Pharmaceuticals’ Key Growth Drivers

  • A Look into GW Pharmaceuticals’ Revenue Trends
    Market Realist9 days ago

    A Look into GW Pharmaceuticals’ Revenue Trends

    Cannabis Stock GW Pharmaceuticals Growing Steadily in January (Continued from Prior Part) ## Revenue trends In the fourth quarter of fiscal 2018, GW Pharmaceuticals (GWPH) generated revenues of $2.42 million compared to $2.45 million in the same period the prior year, reflecting ~1% YoY growth. In fiscal 2018, GW Pharmaceuticals’ net revenues grew ~15.75% YoY to reach $12.74 from $11.00. In the fourth quarter of 2018, GW Pharmaceuticals generated revenues of $10.5 million from product sales compared to $8.0 million in the same period the prior year, reflecting ~32% YoY growth. Wall Street analysts estimate that GW Pharmaceuticals will generate revenues of $8.8 million in the first quarter of fiscal 2019, which represents ~15.75% YoY growth. Analysts also estimate that GW Pharmaceuticals’ net revenues in fiscal 2019 will be around $122.66 million. GW Pharmaceuticals is strengthening its supply chain of Epidiolex. GW Pharmaceuticals’ regulatory filing for approval of Epidiolex in the European market is under review by the European Medicines Agency (or EMA). The company anticipates the EMA’s decision by the first quarter of fiscal 2019. The approval of the drug in the European market could significantly boost the revenue growth of GW Pharmaceuticals. ## Peers’ performance Cara Therapeutics (CARA) and Insys Therapeutics (INSY), GW Pharmaceuticals’ peers in the medical cannabis market, reported revenues of $5.0 million and $18.35 million, respectively, in the third quarter of fiscal 2018. Wall Street analysts estimate that Cara Therapeutics and Insys Therapeutics will report net revenues of $10.9 million and $83.74 million, respectively, in fiscal 2018. The revenue growth of GW Pharmaceuticals, Cara Therapeutics, and Insys Therapeutics could boost the ETFMG Alternative Harvest ETF (MJ). GW Pharmaceuticals, Cara Therapeutics, and Insys Therapeutics make up ~5.95%, ~1.52%, and ~1.64% of MJ’s total portfolio holding. In the next article, we’ll discuss GW Pharmaceuticals’ other earnings and operational expenditure trends. Continue to Next Part Browse this series on Market Realist: * Part 1 - GW Pharmaceuticals Has Already Soared 23% in January * Part 3 - How GW Pharmaceuticals’ Earnings Are Trending * Part 4 - Here Are Some of GW Pharmaceuticals’ Key Growth Drivers

  • GW Pharmaceuticals Has Already Soared 23% in January
    Market Realist9 days ago

    GW Pharmaceuticals Has Already Soared 23% in January

    Cannabis Stock GW Pharmaceuticals Growing Steadily in January ## Stock performance On January 9, GW Pharmaceuticals (GWPH) stock rose ~1.81% to reach $119.54 from its prior day close of $117.41 on January 8. On January 7, the company’s stock price grew ~5.31% to reach $114.66 from its prior day close of $108.66 on January 4, 2019. On January 4, the company’s stock grew ~9.22% to reach $108.88 from its prior day close of $99.69 on January 3, 2019. GW Pharmaceuticals’ price of $119.54 on January 9 represents ~23% growth in the first six trading days of January 2, and this price is 33% below its 52-week high of $179.65 on September 27, 2018. On December 27, 2018, the company hit its 52-week low of $90.14. ## About GW Pharmaceuticals GW Pharmaceuticals is focused on the innovation, development, and commercialization of therapies from the company’s proprietary cannabinoid products. GW Pharmaceuticals’ Epidiolex oral solution has already received the FDA (Food and Drug Administration) approval for the treatment of individuals aged above two years with seizures related to Lennox-Gastaut syndrome or Dravet Syndrome. ## Analysts’ recommendations Of 13 analysts tracking GW Pharmaceuticals (GWPH) in January 2019, three of them recommended a “strong buy,” while eight analysts recommended a “buy” rating. One analyst recommended a “hold” rating, while one analyst recommended a “strong sell” for GW Pharmaceuticals in January. On January 10, GW Pharmaceuticals had a consensus 12-month target price of $173.17, which represents a ~44.86% return on investment over the next 12 months of this year. ## Peer ratings Of the five analysts tracking Supreme Cannabis Company (SPRWF) in January 2019, two of them recommended a “strong buy,” while three analysts recommended a “buy” rating. In January 2019, of the 11 analysts tracking Canopy Growth (CGC), two of them recommended a “strong buy,” seven recommended a “buy,” one recommended a “hold,” and one recommended a “sell” rating. Continue to Next Part Browse this series on Market Realist: * Part 2 - A Look into GW Pharmaceuticals’ Revenue Trends * Part 3 - How GW Pharmaceuticals’ Earnings Are Trending * Part 4 - Here Are Some of GW Pharmaceuticals’ Key Growth Drivers

  • Zacks Market Edge Highlights: Tilray, Constellation Brands, Altria and GW Pharmaceuticals
    Zacks9 days ago

    Zacks Market Edge Highlights: Tilray, Constellation Brands, Altria and GW Pharmaceuticals

    Zacks Market Edge Highlights: Tilray, Constellation Brands, Altria and GW Pharmaceuticals

  • The Wall Street Journal9 days ago

    [$$] Health-Care CEOs Outline Strategies at J.P. Morgan Conference

    One of the biggest health conferences of the year for investors, the J.P. Morgan Health-Care Conference, is taking place this week in San Francisco. BioMarin Pharmaceutical Inc. CEO Jean-Jacques Bienaimé said he would consider pursuing installment payment arrangements for the biotech’s experimental gene therapy for hemophilia. At the conference, Mr. Bienaimé told the Wall Street Journal that the one-time infusion, Valrox, is likely to cost in the millions because studies have shown it can eliminate bleeding episodes in patients, and current hemophilia treatments taken chronically can cost millions over several years.

  • Pot Stocks in 2019: A Year of Transition
    Zacks10 days ago

    Pot Stocks in 2019: A Year of Transition

    In 2018, investors pinned their pot stock hopes on Canadian legalization but in 2019 the game has changed. Who will emerge as the winners?

  • 7 Reasons GW Pharmaceuticals' Epidiolex Will Be a Big Winner
    Motley Fool10 days ago

    7 Reasons GW Pharmaceuticals' Epidiolex Will Be a Big Winner

    GW Pharma CEO Justin Gover gave reasons for optimism about Epidiolex at the J.P. Morgan Healthcare Conference.

  • Which Biopharma Stocks Are Looking To Score Big In Cannabis Medicine?
    Investor's Business Daily14 days ago

    Which Biopharma Stocks Are Looking To Score Big In Cannabis Medicine?

    Now that one cannabis-based drug has won FDA approval, a wide range of drugmakers, from small biotech stocks to giant pharma firms, are exploring the substance to treat a host of maladies.

  • Cannabis, Migraines, Gene-Silencing: FDA Approvals Hit High Note In 2018
    Investor's Business Daily17 days ago

    Cannabis, Migraines, Gene-Silencing: FDA Approvals Hit High Note In 2018

    The Food and Drug Administration approved 59 new drugs in 2018 — hitting at least a four-year record — though fewer biologic drugs passed muster. There were also 17 biologic drugs approved.

  • The Fastest-Growing Marijuana Stocks in 2019
    Motley Fool17 days ago

    The Fastest-Growing Marijuana Stocks in 2019

    These seven pot stocks should deliver at least 400% sales growth in fiscal 2019.

  • GW Pharmaceuticals’ European Launch and Payer Access for Epidiolex
    Market Realist18 days ago

    GW Pharmaceuticals’ European Launch and Payer Access for Epidiolex

    According to GW Pharmaceuticals’ (GWPH) fiscal 2018 fourth-quarter earnings conference call, the company is planning to launch Epidiolex in five major European markets in 2019 after securing regulatory approval from the European Medicines Agency. GW Pharmaceuticals has established a robust commercial leadership team made up of rare disease experts and epilepsy experts to advance precommercial, pricing, reimbursement, and awareness activities for Epidiolex. GW Pharmaceuticals has adopted a hub-and-spoke sales model for the launch of Epidiolex in Europe.

  • Exploring GW’s Label Expansion Initiatives for Epidiolex
    Market Realist19 days ago

    Exploring GW’s Label Expansion Initiatives for Epidiolex

    On November 26, GW Pharmaceuticals (GWPH) announced favorable top line results from its second Phase 3 trial evaluating Epidiolex on top of a patient’s existing treatment for the reduction of convulsive seizures associated with Dravet syndrome. According to the call, GW Pharmaceuticals will be testing both a capsule formulation as well as an improved oral formulation of Epidiolex in Phase 1 trials in 2019.

  • GW Pharmaceuticals Focuses on Epidiolex’s US Commercial Launch
    Market Realist19 days ago

    GW Pharmaceuticals Focuses on Epidiolex’s US Commercial Launch

    On September 5, the US Department of Justice and the Drug Enforcement Administration issued a press release announcing the rescheduling of Epidiolex into Schedule V of the Controlled Substances Act. According to GW Pharmaceuticals’ (GWPH) fiscal 2018 fourth-quarter earnings conference call, the company’s state government affairs team has also ensured the rescheduling of Epdiolex in Washington, D.C., as well as in the 50 US states. According to GW Pharmaceuticals’ earnings conference call, the company has been striving to reach out to 5,000 physicians about increasing the adoption of Epidiolex.

  • Epidiolex Launch Expected to Push Up GW’s Operating Expenses
    Market Realist19 days ago

    Epidiolex Launch Expected to Push Up GW’s Operating Expenses

    On its fiscal 2018 fourth-quarter earnings conference call, GW Pharmaceuticals (GWPH) projected its operating expenses for the quarter that ends on December 31 to fall to the range of $90 million–$100 million, higher than the $83 million it reported in the previous quarter.

  • GlobeNewswire19 days ago

    GW Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference

    GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW’s Chief Executive Officer, will present a company update at the J.P. Morgan 2019 Healthcare Conference in San Francisco, Calif. on Tuesday, January 8, 2019 at 7:30 a.m. PST (10:30 a.m. EST), followed by a Q&A session. Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas.

  • 4 Big-Name Pot Stocks That'll Lose Money in 2019
    Motley Fool20 days ago

    4 Big-Name Pot Stocks That'll Lose Money in 2019

    Soaring sales won't pull these popular marijuana stocks into the black next year.

  • GW Pharmaceuticals Is Expected to Turn Profitable in 2020
    Market Realist21 days ago

    GW Pharmaceuticals Is Expected to Turn Profitable in 2020

    In fiscal 2018, which ended on September 30, GW Pharmaceuticals (GWPH) reported total revenue of $12.74 million, a YoY (year-over-year) rise of 15.75%. Additionally, according to the company’s earnings conference call, it also recognized research and development fee revenue after the termination of its agreement with Otsuka Pharmaceuticals and subsequently reacquired the US rights for Sativex. Wall Street analysts expect GW Pharmaceuticals to report non-GAAP (generally accepted accounting principles) diluted EPS of -$6.26 in fiscal 2019, a YoY rise of 40.69%.

  • Revenue Spike Expected for GW Pharmaceuticals in 2019
    Market Realist22 days ago

    Revenue Spike Expected for GW Pharmaceuticals in 2019

    On its fiscal 2018 fourth-quarter earnings conference call, GW Pharmaceuticals (GWPH) announced the change of the end of its fiscal year from September 30 to the calendar year’s end on December 31. Analysts expect GW Pharmaceuticals to report revenue of $131.30 million in 2019, a YoY (year-over-year) rise of 930.86%. The company is also expected to report revenue of $421.71 million in 2020, a YoY rise of 221.18%.